Many studies have demonstrated that CASP1 may be a therapeutic target against cognitive impairment and inflammation in AD (Kaushal et al., 2015; Gu et al., 2021; Flores et al., 2022). This evidence concerns the gene CASP1 and Cognitive impairment.